Rebecca Simonsen, MD | Authors

Articles

Poor Survival Rates Spur Research in Immunotherapy Combinations, PARP Inhibitors in SCLC

November 02, 2019

Despite advances in small cell lung cancer, overall 5-year survival remains at 5% to 10%. At the time of presentation, approximately 30% of patients with SCLC have limited stage disease, which is confined to the mediastinum, the hemithorax, or the supraclavicular lymph nodes. The remaining patients, who have extensive-stage SCLC, have tumors beyond the supraclavicular areas.